Traitors of the immune system-Enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development

Vaccine

Volumn 26, Issue 24, 2008, Pages 3078-3085

  Beck, Zoltán ^a   Prohászka, Zoltán ^a   Füst, George ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

Antibodies; C ADE; Complement; Enhancement; Enhancing; Fc receptor; HIV; Vaccine

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; BLUETONGUE ORBIVIRUS; CLINICAL TRIAL; DENGUE VIRUS; DISEASE COURSE; DISEASE SEVERITY; EBOLA VIRUS; ENDOTHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFLUENZA VIRUS; LENTIVIRINAE; MACROPHAGE; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; ANTIBODY-DEPENDENT ENHANCEMENT; COMPLEMENT SYSTEM PROTEINS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MACACA MULATTA; RECEPTORS, COMPLEMENT;

EID: 44649191357     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.028     Document Type: Article

References (56)

1. McCarthy M. AIDS vaccine fails in Thai trial. Lancet 362 9397 (2003) 1728
2. McCarthy M. HIV vaccine fails in phase 3 trial. Lancet 361 9359 (2003) 755-756
3. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 318 5847 (2007) 28-29
4. Davenport M.P., Ribeiro R.M., Chao D.L., and Perelson A.S. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78 20 (2004) 11340-11351
5. Lee D., Graham B.S., Chiu Y.L., Gilbert P.B., McElrath M.J., Belshe R.B., et al. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis 190 5 (2004) 903-907
6. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191 5 (2005) 654-665
7. Porterfield J.S. Antibody-dependent enhancement of viral infectivity. Adv Virus Res 31 (1986) 335-355
8. Fust G. Enhancing antibodies in HIV infection. Parasitology 115 Suppl (1997) S127-S140
9. Tirado S.M., and Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16 1 (2003) 69-86
10. Halstead S.B. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140 4 (1979) 527-533
11. Halstead S.B., Nimmannitya S., and Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 42 5 (1970) 311-328
12. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 239 4839 (1988) 476-481
13. Burke D.S., Nisalak A., Johnson D.E., and Scott R.M. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 38 1 (1988) 172-180
14. Kliks S.C., Nisalak A., Brandt W.E., Wahl L., and Burke D.S. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 40 4 (1989) 444-451
15. Pang T., Cardosa M.J., and Guzman M.G. Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS). Immunol Cell Biol 85 1 (2007) 43-45
16. Gollins S.W., and Porterfield J.S. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321 6067 (1986) 244-246
17. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 1 (2000) 2-9
18. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189 6 (2004) 990-1000
19. Cardosa M.J., Porterfield J.S., and Gordon S. Complement receptor mediates enhanced flavivirus replication in macrophages. J Exp Med 158 1 (1983) 258-263
20. Chanock R.M., Kapikian A.Z., Mills J., Kim H.W., and Parrott R.H. Influence of immunological factors in respiratory syncytial virus disease. Arch Environ Health 21 3 (1970) 347-355
21. Ponnuraj E.M., Springer J., Hayward A.R., Wilson H., and Simoes E.A. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the Bonnet monkey model. J Infect Dis 187 8 (2003) 1257-1263
22. Takada A., Feldmann H., Ksiazek T.G., and Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol 77 13 (2003) 7539-7544
23. Iankov I.D., Pandey M., Harvey M., Griesmann G.E., Federspiel M.J., and Russell S.J. Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80 17 (2006) 8530-8540
24. Pletz M.W., Dickgreber N., Hagen L., Golpon H., Zabel P., Bauer T.T., et al. Immunisation strategies for the management of severe acute respiratory syndrome (SARS). Pneumologie 61 10 (2007) 663-667
25. Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. A human immunodeficiency virus type 1 (HIV-1) infection-enhancing factor in seropositive sera. Biochem Biophys Res Commun 149 2 (1987) 693-699
26. Robinson Jr. W.E., Montefiori D.C., and Mitchell W.M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1 8589 (1988) 790-794
27. Gras G.S., and Dormont D. Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol 65 1 (1991) 541-545
28. Robinson Jr. W.E., Montefiori D.C., Gillespie D.H., and Mitchell W.M. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J Acquir Immune Defic Syndr 2 1 (1989) 33-42
29. Takeda A., Tuazon C.U., and Ennis F.A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242 4878 (1988) 580-583
30. Homsy J., Meyer M., Tateno M., Clarkson S., and Levy J.A. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 244 4910 (1989) 1357-1360
31. Homsy J., Meyer M., and Levy J.A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 64 4 (1990) 1437-1440
32. Hessell A.J., Hangartner L., Hunter M., Havenith C.E., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 7158 (2007) 101-104
33. Robinson Jr. W.E., Kawamura T., Gorny M.K., Lake D., Xu J.Y., Matsumoto Y., et al. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci USA 87 8 (1990) 3185-3189
34. Robinson Jr. W.E., Kawamura T., Lake D., Masuho Y., Mitchell W.M., and Hersh E.M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 64 11 (1990) 5301-5305
35. Prohaszka Z., Hidvegi T., Ujhelyi E., Stoiber H., Dierich M.P., Susal C., et al. Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1. Immunology 85 2 (1995) 184-189
36. Robinson Jr. W.E., Gorny M.K., Xu J.Y., Mitchell W.M., and Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol 65 8 (1991) 4169-4176
37. Mitchell W.M., Ding L., and Gabriel J. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV. Aids 12 2 (1998) 147-156
38. Robinson W.E. Mechanism for complement-mediated, antibody-dependent enhancement of human immunodeficiency virus type 1 infection in MT2 cells is enhanced entry through CD4, CD21, and CXCR4 chemokine receptors. Viral Immunol 19 3 (2006) 434-447
39. Prohaszka Z., Nemes J., Hidvegi T., Toth F.D., Kerekes K., Erdei A., et al. Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection. Aids 11 8 (1997) 949-958
40. Gardner M.B., Rosenthal A., Jennings M., Yee J.A., Antipa L., and MacKenzie M. Passive immunization of macaques against SIV infection. J Med Primatol 23 2-3 (1994) 164-174
41. Gardner M., Rosenthal A., Jennings M., Yee J., Antipa L., and Robinson Jr. E. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res Hum Retroviruses 11 7 (1995) 843-854
42. Mitchell W.M., Torres J., Johnson P.R., Hirsch V., Yilma T., Gardner M.B., et al. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. Aids 9 1 (1995) 27-34
43. Subbramanian R.A., Xu J., Toma E., Morisset R., Cohen E.A., Menezes J., et al. Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients. J Clin Microbiol 40 6 (2002) 2141-2146
44. Toth F.D., Szabo B., Ujhelyi E., Paloczi K., Horvath A., Fust G., et al. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. Aids 5 3 (1991) 263-268
45. Szabo J., Prohaszka Z., Toth F.D., Gyuris A., Segesdi J., Banhegyi D., et al. Strong correlation between the complement-mediated antibody-dependent enhancement of HIV-1 infection and plasma viral load. Aids 13 14 (1999) 1841-1849
46. Fust G., Toth F.D., Kiss J., Ujhelyi E., Nagy I., and Banhegyi D. Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease. Aids 8 5 (1994) 603-609
47. Banhegyi D., Bacsi A., Toth F.D., Prohaszka Z., Horvath A., Beck Z., et al. Significant decrease of the enhancement/neutralization index in HIV patients during highly active antiretroviral therapy (HAART). Immunol Lett 89 1 (2003) 25-30
48. Montefiori D.C., Lefkowitz Jr. L.B., Keller R.E., Holmberg V., Sandstrom E., and Phair J.P. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. Aids 5 5 (1991) 513-517
49. Montefiori D.C., Pantaleo G., Fink L.M., Zhou J.T., Zhou J.Y., Bilska M., et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 173 1 (1996) 60-67
50. Verrier F., Moog C., Barre-Sinoussi F., Van der Ryst E., Spenlehauer C., and Girard M. Macaque immunization with virions purified from a primary isolate of the human immunodeficiency virus type 1 induced enhancement antibodies. Bull Acad Natl Med 184 1 (2000) 67-84 discussion 85-7
51. Haigwood N.L., Montefiori D.C., Sutton W.F., McClure J., Watson A.J., Voss G., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 78 11 (2004) 5983-5995
52. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101 35 (2004) 13026-13031
53. Keefer M.C., Graham B.S., Belshe R.B., Schwartz D., Corey L., Bolognesi D.P., et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. AIDS Res Hum Retroviruses 10 12 (1994) 1713-1723
54. Dolin R., Graham B.S., Greenberg S.B., Tacket C.O., Belshe R.B., Midthun K., et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network. Ann Intern Med 114 2 (1991) 119-127
55. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191 5 (2005) 666-677
56. Graham B.S., and Mascola J.R. Lessons from failure - preparing for future HIV-1 vaccine efficacy trials. J Infect Dis 191 5 (2005) 647-649